NCT07001319 - Study of GS-3242 in Participants With HIV-1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 29, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2027

Conditions

HIV-1-infection

Interventions

DRUG

GS-3242

Administered orally

DRUG

BVY

Administered orally

DRUG

Standard of Care

Antiretroviral therapy, administered orally Non-NNRTIs, examples: ABC/ DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)

Trial Locations (18)

20017

RECRUITING

Washington Health Institute,Substudy-05, Washington D.C.

31401

RECRUITING

Chatham County Health Department,Substudy-05, Savannah

32720

RECRUITING

Midland Florida Clinical Research Center, LLC,Substudy-05, DeLand

32803

RECRUITING

BLISS Health,Substudy-05, Orlando

RECRUITING

Orlando Immunology Center, PA,Substudy-05, Orlando

33407

RECRUITING

Triple O Research Institute, P.A.,Substudy-05, West Palm Beach

34982

RECRUITING

Midway Immunology & Research Center, LLC, Ft. Pierce

45267

RECRUITING

University of Cincinnati College of Medicine, Cincinnati

46202

RECRUITING

Indiana University School of Medicine, Indianapolis

48072

RECRUITING

Be Well Medical Center, Berkley

75208

RECRUITING

Prism Health North Texas,Substudy-05, Dallas

75246

RECRUITING

North Texas Infectious Diseases Consultant's, P.A.,Substudy-05, Dallas

78705

RECRUITING

Central Texas Clinical Research,Substudy-05, Austin

79902

RECRUITING

AXCES Research Group, LLC, El Paso

84102

RECRUITING

AXCES Research Group, LLC, Salt Lake City

90036

RECRUITING

Ruane Clinical Research Group, Inc, Los Angeles

90069

RECRUITING

Mills Clinical Research, Los Angeles

94115

RECRUITING

Quest Clinical Research,Substudy-05, San Francisco